Market Research Logo

Refractory Acute Myeloid Leukemia Global Clinical Trials Review, H1, 2018

Refractory Acute Myeloid Leukemia Global Clinical Trials Review, H1, 2018

Summary

GlobalData's clinical trial report, “Refractory Acute Myeloid Leukemia Global Clinical Trials Review, H1, 2018 provides an overview of Refractory Acute Myeloid Leukemia clinical trials scenario. This report provides top line data relating to the clinical trials on Refractory Acute Myeloid Leukemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


  • Report Guidance
  • GlobalData Clinical Trials Report Coverage
  • Clinical Trials by Region
    • Table Figure 1: Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Region (%), 2018*
    • Table Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Region, 2018*
    • Clinical Trials and Average Enrollment by Country
      • Table Figure 2: Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018*
      • Table Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018*
      • Table Figure 3: Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018*
      • Table Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018*
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
        • Table Figure 4: Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018*
        • Table Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018*
      • Top Five Countries Contributing to Clinical Trials in Europe
        • Table Figure 5: Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018*
        • Table Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Europe, Top Five Countries, 2018*
      • Top Countries Contributing to Clinical Trials in North America
        • Table Figure 6: Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, North America, Top Countries (%), 2018*
        • Table Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, North America, Top Countries, 2018*
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
        • Table Figure 7: Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018*
        • Table Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018*
      • Top Five Countries Contributing to Clinical Trials in Central and South America
        • Table Figure 8: Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018*
        • Table Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018*
  • Clinical Trials by G7 Countries: Proportion of Refractory Acute Myeloid Leukemia to Oncology Clinical Trials
    • Table Figure 9: Proportion of Refractory Acute Myeloid Leukemia to Oncology Clinical Trials, G7 Countries (%), 2018*
    • Table Proportion of Refractory Acute Myeloid Leukemia to Oncology Clinical Trials, G7 Countries (%), 2018*
  • Clinical Trials by Phase in G7 Countries
    • Table Figure 10: Refractory Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2018*
    • Table Refractory Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2018*
  • Clinical Trials in G7 Countries by Trial Status
    • Table Figure 11: Refractory Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018*
    • Table Refractory Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018*
  • Clinical Trials by E7 Countries: Proportion of Refractory Acute Myeloid Leukemia to Oncology Clinical Trials
    • Table Figure 12: Proportion of Refractory Acute Myeloid Leukemia to Oncology Clinical Trials, E7 Countries (%), 2018*
    • Table Proportion of Refractory Acute Myeloid Leukemia to Oncology Clinical Trials, E7 Countries (%), 2018*
  • Clinical Trials by Phase in E7 Countries
    • Table Figure 13: Refractory Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2018*
    • Table Refractory Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2018*
  • Clinical Trials in E7 Countries by Trial Status
    • Table Figure 14: Refractory Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018*
    • Table Refractory Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018*
  • Clinical Trials by Phase
    • Table Figure 15: Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Phase (%), 2018*
    • Table Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Phase, 2018*
    • In Progress Trials by Phase
      • Table Figure 16: Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Phase, 2018*
      • Table Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Phase 2018*
  • Clinical Trials by Trial Status
    • Table Figure 17: Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Trial Status, 2018*
    • Table Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Trial Status, 2018*
  • Clinical Trials by End Point Status
    • Table Figure 18: Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, by End Point Status, 2018*
    • Table Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, by End Point Status, 2018*
  • Subjects Recruited Over a Period of Time
    • Table Figure 19: Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013- 2017
    • Table Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013- 2017
  • Clinical Trials by Sponsor Type
    • Table Figure 20: Refractory Acute Myeloid Leukemia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018*
    • Table Refractory Acute Myeloid Leukemia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018*
  • Prominent Sponsors
    • Table Figure 21: Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Key Sponsors, 2018*
    • Table Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Key Sponsors, 2018*
    • Top Companies Participating in Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials
      • Table Figure 22: Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018*
      • Table Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018*
  • Prominent Drugs
    • Table Figure 23: Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018*
    • Table Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018*
  • Latest Clinical Trials News on Refractory Acute Myeloid Leukemia
    • Jun 26, 2018: Actinium Pharmaceuticals Announces Dosing of 38th Patient and 25 Percent Enrollment in Iomab-B Pivotal SIERRA Trial
    • Jun 16, 2018: Phase 3 QuANTUM-R Study Demonstrates Daiichi Sankyos Quizartinib Significantly Prolongs Overall Survival as Single Agent Compared to Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations
    • Jun 15, 2018: Tolero Pharmaceuticals Presents Clinical Data for Investigational Agent Alvocidib in Patients with Relapsed Refractory MCL-1-Dependent AML at EHA 2018
    • Jun 13, 2018: Actinium Pharmaceuticals Announces Treatment of First Patient in Novel Combination Trial of Actimab-A Plus CLAG-M
    • Jun 12, 2018: EHA Late-Breaking, Plenary Presentation: Quizartinib Significantly Prolongs Overall Survival in Pivotal, Phase 3 AML Study
    • Jun 06, 2018: Daiichi Sankyo to Present Late-Breaking Phase 3 Data for Single Agent Quizartinib in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations at Plenary Session at EHA 2018
    • Jun 02, 2018: Updated Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1m Relapsed or Refractory AML Continue to Show Durable Responses as a Single Agent
    • May 17, 2018: Forty Seven to Present Preliminary Data from its Ongoing Phase 1 Clinical Trial of 5F9 in Acute Myeloid Leukemia at the 23rd Congress of the European Hematology Association
    • May 17, 2018: BioLineRx to Present Overall Survival Data at EHA from Phase 2a Study of BL-8040 in r/r AML Patients
    • May 16, 2018: Moleculin to Begin Clinical Trials at UMC Southwest Cancer Center
    • May 16, 2018: Agios to Present Clinical Data on Ivosidenib at ASCO
    • May 15, 2018: Race executes agreement for Bisantrene clinical trial
    • May 08, 2018: Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared with Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations (QuANTUM-R Study)
    • May 01, 2018: Aptevo Therapeutics Announces IND Submission for APVO436
    • Apr 27, 2018: Haematologica publishes Celyad THINK Study Case Report of CYAD-01 Induced Complete Remission in Relapsed/Refractory AML Patient
    • Apr 16, 2018: Selvita publishes research results on SEL24 in Oncotarget
    • Apr 12, 2018: Clinical Cancer Research Publishes Phase I Data from a Study of Rafael Pharmaceuticals' Lead CPI-613 Compound in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia
    • Apr 11, 2018: ADC Therapeutics to Present on its Lymphoid Malignancies Drug Candidate DCT-301 at the American Association for Cancer Research (AACR) Annual Meeting
    • Apr 09, 2018: Amgen To Present New Pre-Clinical Data Showcasing Robust Approach To Evaluating Potential Anti-Cancer Therapies At AACR 2018
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
      • Table Figure 24: GlobalData Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
  • Source

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report